TipRanks ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
TipRanks (Wed, 27-Mar 6:25 AM ET)
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
TipRanks (Wed, 27-Mar 6:25 AM ET)
TipRanks (Sun, 24-Mar 9:47 PM ET)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 20-Mar 7:30 AM ET)
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
Globe Newswire (Tue, 5-Mar 11:53 PM ET)
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
Globe Newswire (Mon, 4-Mar 4:17 PM ET)
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
Globe Newswire (Mon, 4-Mar 2:30 AM ET)
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Globe Newswire (Thu, 22-Feb 7:30 AM ET)
Globe Newswire (Wed, 7-Feb 7:34 AM ET)
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Bridgebio Pharma trades on the NASDAQ stock market under the symbol BBIO.
As of March 28, 2024, BBIO stock price declined to $30.66 with 823,538 million shares trading.
BBIO has a beta of 2.45, meaning it tends to be more sensitive to market movements. BBIO has a correlation of 0.12 to the broad based SPY ETF.
BBIO has a market cap of $5.66 billion. This is considered a Mid Cap stock.
Last quarter Bridgebio Pharma reported $2 million in Revenue and -$.96 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.05.
In the last 3 years, BBIO stock traded as high as $65.33 and as low as $4.98.
The top ETF exchange traded funds that BBIO belongs to (by Net Assets): VTI, VB, IWM, XBI, VBR.
BBIO has outperformed the market in the last year with a price return of +114.1% while the SPY ETF gained +33.8%. However, in the short term, BBIO had mixed performance relative to the market. It has underperformed in the last 3 months, returning -30.1% vs +10.3% return in SPY. But in the last 2 weeks, BBIO shares have fared better than the market returning +8.8% compared to SPY +1.9%.
BBIO support price is $29.70 and resistance is $32.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BBIO stock will trade within this expected range on the day.